Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO: Patisiran in hATTR amyloidosis with polyneuropathy
NCT01960348Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Aug 2017
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 21
01
Overview
A Phase 3 trial of patisiran in hereditary transthyretin amyloidosis (hATTR), sponsored by Alnylam Pharmaceuticals. Started Nov 2013; status: completed.
02
Drugs
patisiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NCT01960348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01960348.